Troglitazone inhibits long-term glycation and oxidation of low-density lipoprotein

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 5, 2005, Pages 672-680

  Sobal, Grazyna ^a   Menzel, E J ^b   Sinzinger, H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

8 epi PGF2 ; Diabetes mellitus; Glycation; Glycoxidation; Isoprostanes; Low density lipoprotein; Oxidation; Troglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 HYDROXYMETHYLFURFURAL; 8 ISOPROSTAGLANDIN F2 ALPHA; ADVANCED GLYCATION END PRODUCT; ANTIDIABETIC AGENT; CELL PROTEIN; COPPER; FRUCTOSAMINE; ISOPROSTANE DERIVATIVE; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TROGLITAZONE;

ADULT; ARTICLE; CATALYSIS; CELL ADHESION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG CYTOTOXICITY; ELECTROPHORETIC MOBILITY; ENDOTHELIUM CELL; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INHIBITION KINETICS; LIGAND BINDING; LIPOPROTEIN METABOLISM; MALE; NORMAL HUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION;

ADULT; CATALYSIS; CELL SURVIVAL; CELLS, CULTURED; CHROMANS; ENDOTHELIAL CELLS; FEMALE; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 27344442751     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000182623.89196.62     Document Type: Article

References (46)

1. Steiner C. Atherosclerosis, the major complication of diabetes. Adv Exp Med Biol. 1985;189:277-297.
2. Cominacini L, Garbin U, Pastorino AM. Increased susceptibility of LDL to in vitro oxidation in patients with insulin-dependent and non-insulin-dependent diabetes mellitus. Diabetes Res. 1994;26:173-184.
3. Bucala R, Makita Z, Koschinsky T, et al. Lipid advanced glycosylation: pathway for lipid oxidation in-vivo. Proc Natl Acad Sci USA. 1993;90: 6434-6438.
4. Menzel EJ, Sobal G, Staudinger A. The role of oxidative stress in the long-term glycation of LDL. Biofactors. 1997;6:111-124.
5. Sobal G, Menzel EJ, Sinzinger H. Why is glycated LDL more sensitive to oxidation than native LDL? A comparative study. Prostaglandins Leukot Essent Fatty Acids. 2000;63:177-186.
6. Bucala R, Makita Z, Vega G, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA. 1994;91:9441-9445.
7. Stevenson RW, Hutson NJ, Krupp MN, et al. Actions of a novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic 0b/0b mice. Diabetes. 1990;39:1218-1227.
8. Castle CK, Colca JR, Melchior GW. Lipoprotein profile characterization of the KKA mouse, a rodent model of type II diabetes, before and after treatment with the insulin-sensitizing agent pioglitazone. Arterioscler Thromb. 1992;13:307-309.
9. Lee MK, Miles PDG, Khoursheed M, et al. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes. 1994;43:1435-1439.
10. Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331:1188-1193.
11. Fujita T, Sugiyama Y, Taketomi S. Reduction of insulin resistance in obese and/or diabetic animals by 3[-4-(1-methylcyclohexylmethoxy) benzyl]-thiazolidine-2,4 dione (ciglitazone), a new antidiabetic agent. Diabetes. 1983;32:804-810.
12. Fujiwara T, Yoshioka S, Yoshioka T, et al. Characterization of a new antidiabetic agent, CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 1988;37:1549-1558.
13. Suter SL, Nolan JJ, Wallace P, et al. Metabolic effects of a new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 1992; 15:193-203.
14. Kurebayashi S, Hirose T, Miyashita Y, et al. Thiazolidinediones downregulate stearoyl-CoA desaturase 1 gene expression in 3T3-L1 adipocytes. Diabetes. 1997;46:2115-2118.
15. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
16. Horikoshi H, Yoshioka T, Kawasaki T, et al. Troglitazone (CS-045), a new antidiabetic drug. Annu Rep Sankyo Res Lab. 1994;46:1-57.
17. Cominacini L, Young MMR, Capriati A, et al. Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers. Diabetologia. 1997;4:1211-1218.
18. Inoue I, Katayama S, Takahashi K, et al. T has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun. 1997;235:113-116.
19. Yoshioca T, Fujita T, Kanai T. Studies on hindered phenols and analogues. I. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J Med Chem. 1989;32:421-427.
20. Watanabe H. ESR studies on the antioxidant activity of troglitazone. Chem Pharm Bull (Tokyo). 1997;45:1851-1855.
21. Cominacini L, Garbin U, Pastorino AM, et al. Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells. Diabetologia. 1997;40:165-172.
22. Cominacini L, Garbin U, Pasini AF. Troglitazone reduces LDL-oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes. 1998;47:130-133.
23. Morrow JD, Hill KE, Burk RF. A series of prostaglandin F2-like compounds are produced in- vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA. 1990;87:9383-9387.
24. Morrow JD, Harris TM, Roberts LJ. II, Non-cyclooxygenase oxidative formation of a series of novel prostaglandins: Analytical ramifications for measurement of eicosanoids. Anal Biochem. 1990;184:1-10.
25. 2α, in rabbit lung in situ. Am J Physiol. 1992;263:H660-H663.
26. 2α, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins. 1992;44:155-163.
27. Leitinger N, Blazek I, Sinzinger H. The influence of isoprostanes on ADP-induced platelet aggregation and cyclic AMP-generation in human pletelets. Thromb Res. 1997;86:337-342.
28. 2α levels are elevated in individuals with NIDDM. FEBS Lett. 1995;368:225-229.
29. 1c. FEBS Lett. 1976;71:356-360.
30. Neumüller J, Menzel EJ. In: Pollard JW, Walker JM, eds. Methods in Molecular Biology, vol. 75: Basic Cell Culture Protocols. Totowa, NJ: Humana Press Inc.; 1997:399-425.
31. Menzel EJ, Sobal G, Staudinger A. The role of oxidative stress in the long-term glycation of LDL. Biofactors. 1997;6:111-124.
32. Sobal G, Sinzinger H, Menzel EJ. Troglitazone-binding to LDL and its glycated modifications: its role in cell-catalysed and Cu-mediated LDL-oxidation. Life Sci. 2000;67:695-707.
33. Thomas ST, Neuzil J, Mohr D, et al. Coantioxidants make α-tocopherol an efficient antioxidant for low-density lipoprotein. Am J Clin Nutr. 1995;62: 1357-1364.
34. Preobrazhensky S, Trakht I, Chestkov V, et al. Monoclonal antibody-based immunoassay for evaluation of lipoprotein oxidation. Anal Biochem. 1995; 227:225-234.
35. Tsai M, Hirsch IB, Brunzell JD, et al. Lower plasma peroxyl trapping capacity and higher susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes. 1994;43:1010-1014.
36. Yamazaki H, Suzuki M, Tane K, et al. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica. 2000;30:61-70.
37. Young PW, Buckle DR, Cantello BC, et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ. J Pharmacol Exp Ther. 1998;284:751-759.
38. Wang M, Wise SC, Leff T, et al. Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-γ. Diabetes. 1999;48:254-260.
39. Tontonoz P, Nagy L. Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor γ: implications for cardiovascular disease. Curr Opin Lipidol. 1999;10:485-490.
40. Matsumoto K, Hirano K, Nozaki S, et al. Expression of macrophage (Mφ) scavenger receptor, CD36, in cultured human aortic smooth muscle cells in association with expression of peroxisome proliferator activated receptor-γ, which regulates gain of Mφ-like phenotype in vitro, and its implication in atherogenesis. Arterioscler Thromb Vasc Biol. 2000;20: 1027-1032.
41. Nagy L, Tontonoz P, Alvarez JG, et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-γ. Cell. 1998; 93:229-240.
42. Endemann G, Stanton LW, Madden K.S, et al. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993;268:11811-11816.
43. Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998;83:1818-1820.
44. Knock GA, Mishra SK, Aaronson PI. Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes. Eur J Pharmacol. 1999;368:103-109.
45. Crawford RS, Mudaliar SR, Henry RR, et al. Inhibition of LDL oxidation in vitro but not ex vivo by troglitazone. Diabetes. 1999;48:783-790.
46. Ziouzenkova O, Gieseg SP, Esterbauer H. Factors affecting resistance of low density lipoproteins to oxidation. Lipids. 1996;31:S-71-S-76.